Tetherex Pharmaceuticals Corp is a clinical-stage development biopharmaceutical company focused on development of therapeutics for the treatment of inflammation, thrombosis and tumor metastasis across a broad range of severe diseases.
Tetherex is committed to advancing the understanding of inflammation in various disease processes and developing novel products to treat thrombosis, inflammatory diseases and cancer.
Tetherex was founded in 2014 as a spin-off of Selexys Pharmaceuticals to develooment. The compan is base in Minneapolis, Annesota, with an additional office in Morrisville, North Carolina.
Tetherex's mission is focused on helping patients who suffer these afflictions enjoy better and longer lives.
Tetherex is a pioneering work on the molecular mechanisms of inflammation has led to breakthroughs in novel therapeutic candidates for inflammatory and thrombotic diseases and positioned Tetherex with strong scientific underpinnings.
Tetherex Pharmaceuticals is backed by MPM Capital & Phil Jones.